Genzyme Corporation (GENZ) Receives Positive CHMP Opinion for LEMTRADA (alemtuzumab) in Europe
6/28/2013 9:37:36 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of LEMTRADA™ (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
Help employers find you! Check out all the jobs and post your resume.
comments powered by